Core Viewpoint - Praxis Precision Medicines has received FDA acceptance for priority review of its New Drug Application for relutrigine, aimed at treating SCN2A and SCN8A developmental and epileptic encephalopathies, with a target action date set for September 27, 2026 [1][2] Group 1: Drug Development and Approval - The NDA for relutrigine is supported by positive results from the EMBOLD study, which was halted early due to efficacy, indicating strong potential for the drug [3] - If approved, relutrigine will be the first disease-modifying therapy for SCN2A/8A DEEs, addressing a significant unmet medical need as there are currently no approved targeted therapies for these conditions [2][3] - Relutrigine has received multiple designations from the FDA, including Orphan Drug Designation, Rare Pediatric Disease Designation, and Breakthrough Therapy Designation, enhancing its development profile [3][5] Group 2: Clinical Trials and Efficacy - The EMERALD trial is ongoing to investigate relutrigine's efficacy in broader DEEs, with completion expected by the end of 2026 [4] - In vivo studies have shown that relutrigine can achieve dose-dependent inhibition of seizures, with some models demonstrating complete control of seizure activity [5] - Data from the Phase 2 EMBOLD study indicated a well-tolerated treatment with significant short- and long-term improvements in motor seizures among heavily pre-treated patients [5] Group 3: Company Overview - Praxis Precision Medicines is a leading CNS precision neuroscience biopharmaceutical company focused on developing therapies for CNS disorders through its proprietary platforms [6] - The company has established a diversified portfolio that includes multiple programs across movement disorders and epilepsy, with four late-stage product candidates [6]

Financial Performance - Praxis Precision Medicines reported a cash balance of $926 million at the end of Q4 2025, with an extended cash runway expected to fund operations into 2028 following a $621 million financing in January [1][4] - R&D expenses increased to $267.1 million for the full year due to intensified clinical activity [1] Product Development and Regulatory Progress - The company submitted two NDAs to the FDA for ulixacaltamide and relutrigine, both of which have received Breakthrough Therapy Designation [2] - Ulixacaltamide is the first investigational therapy to show positive Phase 3 results for essential tremor [2] - Praxis is advancing several programs through its Cerebrum and Solidus platforms, with vormatrigine expected to yield Phase 3 topline results in Q2 2026 and elsunersen on track for Phase 1/2 results in H1 2026 [4] Strategic Initiatives - The company has expanded its leadership team and Board of Directors to support upcoming commercial launches and long-term clinical strategy [1] - Praxis intends to nominate three new development candidates by mid-2026 to address conditions such as autism spectrum disorders and intellectual disabilities, with regulatory submissions planned for the next two years [4]

Summary of Praxis Precision Medicines FY Conference Call Company Overview - **Company**: Praxis Precision Medicines (NasdaqGS:PRAX) - **Key Products**: ULYXIA (for essential tremor), relutrigine (for epilepsy) Core Industry Insights - **Market Size**: The addressable market for essential tremor is over 2 million patients at peak, significantly larger than previously anticipated [15][16] - **Regulatory Strategy**: The company opted for a standard review process for ULYXIA instead of a priority review to maintain a strong relationship with the FDA and maximize revenue potential before IRA negotiations begin [15][16] Key Points Discussed 1. **NDA Submission**: The NDA for ULYXIA has been submitted, and the company is not requesting priority review, anticipating a standard review process [7][15] 2. **FDA Relationship**: The company has maintained continuity in its interactions with the FDA, with no significant staff changes in the review team since the end of Phase 2 meetings [19][20] 3. **Titration Schedule**: The NDA submission included a standard titration schedule, with a proposal to allow clinicians to maintain a 20-milligram dose for an extra week if tolerability issues arise [30][34] 4. **Patient Tolerability**: Approximately 30% of patients may experience dizziness, which could lead to discontinuation of the drug; however, the company believes that maintaining the 20-milligram dose could resolve this issue for most patients [32][34] 5. **Pre-Launch Activities**: The company is focusing on disease awareness and prescriber identification to prepare for the ULYXIA launch, targeting over 200,000 patients interested in clinical trials [58][71] 6. **Sales Force Strategy**: The company plans to hire around 300 sales representatives to ensure adequate coverage and demand generation for ULYXIA, rather than starting with a smaller team and scaling up [126][127] 7. **Pricing Strategy**: The pricing for ULYXIA is expected to reflect its innovative nature, with a potential starting point in the mid-range of existing treatments for similar conditions [112][114] 8. **Relutrigine Development**: The company is also preparing for the launch of relutrigine, which is expected to receive priority review, with a PDUFA date likely in Q4 [135] Additional Important Insights - **Market Dynamics**: The company anticipates a large volume of patients seeking treatment for essential tremor, with about 1 million patients seen by neurologists annually for prescriptions [76][77] - **Community Engagement**: The company is focusing on building relationships with both specialized centers and community neurologists to ensure effective patient referrals and education [140][141] - **Future Data Catalysts**: Upcoming data from the POWER1 study for vormatrigine is expected to show significant efficacy, with a target of 30% placebo-adjusted seizure reduction [152][154] - **Ongoing Studies**: The phase 3 study for Elsunersen is progressing well, with an amendment to remove sham controls based on FDA recommendations [160][162] This summary encapsulates the key discussions and strategic insights from the Praxis Precision Medicines FY Conference Call, highlighting the company's focus on regulatory strategy, market preparation, and product development.

Company Overview - Praxis Precision Medicines is a Boston-based biotechnology company focused on developing novel therapies for neurological and psychiatric disorders characterized by neuronal imbalance [6] - The company has a pipeline targeting major depressive disorder, essential tremor, and rare epilepsies, emphasizing precision medicine and targeted treatments [6] - As of February 17, 2026, the company's stock price was $328.04, reflecting a significant increase of 320% over the prior year [8] Financial Performance - The company reported a trailing twelve months (TTM) revenue of $7.46 million and a net income loss of $273.04 million [4] - Praxis ended 2025 with $926 million in cash and investments, supplemented by an additional $621 million in financing in January 2026, extending its financial runway into 2028 [10][11] - Research and development spending for 2025 reached $267 million, indicating a late-stage push across multiple programs [11] Recent Developments - On February 17, 2026, Perceptive Advisors LLC disclosed a purchase of 431,432 shares of Praxis Precision Medicines, valued at approximately $80.34 million, increasing its stake significantly [2] - The quarter-end value of Perceptive Advisors' position in Praxis increased by $505.38 million due to the share purchase and subsequent stock price movement [2] - Praxis has submitted two New Drug Applications (NDAs) to the FDA for ulixacaltamide in essential tremor and relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) [10] Market Position and Strategy - The company operates a biopharmaceutical business model focused on research, clinical development, and commercialization of proprietary drug candidates [9] - Praxis targets healthcare providers and specialists in neurology and psychiatry, aiming to address unmet medical needs in these fields [9] - The recent increase in portfolio weightings for Praxis reflects a transition from a pipeline story to a pending commercial launch, indicating potential for rapid changes in investor sentiment [7]

Financial Data and Key Metrics Changes - In Q4 2025, operating expenses totaled $97 million, up from $71.4 million in Q4 2024, with R&D expenses increasing from $56.3 million to $77.5 million and G&A expenses rising from $15.1 million to $19.5 million [17][18] - For the full year 2025, operating expenses reached $326 million, compared to $209 million in 2024, driven by increased spending on clinical programs [17][18] - The company ended Q4 2025 with $926 million in cash and equivalents, a significant increase from $469 million at the end of 2024, bolstered by proceeds from public offerings [18][19] Business Line Data and Key Metrics Changes - The ulixacaltamide program reported positive results from the Essential3 program, leading to an NDA submission for essential tremor, with a potential market of over $10 billion annually [9][10] - The relutrigine program for SCN2A and SCN8A DEEs has an initial addressable population of approximately 10,000 patients, with potential annual revenue estimated at $5 billion [12] - Vormatrigine demonstrated a 58% reduction in seizures at week 1 in the RADIANT phase 2 study, with potential annual revenue exceeding $4 billion [14] Market Data and Key Metrics Changes - The addressable population for ulixacaltamide in the U.S. is estimated at 2 million patients with essential tremor, while the broader DEE population for relutrigine is over 200,000 patients [9][12] - The company is preparing for a significant commercial launch, focusing on disease awareness and inventory management for ulixacaltamide and relutrigine [22][31] Company Strategy and Development Direction - The company aims to transform into a commercial entity, with plans to submit two NDAs and enhance its clinical portfolio in 2026 [5][6] - A comprehensive medical education campaign is planned for the upcoming American Academy of Neurology annual meeting to raise awareness about ulixacaltamide [10][25] - The company is focused on building a strong commercial organization and ensuring sufficient inventory for product launches [22][31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming year, highlighting the potential for multiple readouts from the clinical pipeline and the importance of executing pre-commercial activities [16][17] - The company is well-capitalized with a strong balance sheet, expecting to fund operations into 2028 [19] - Management emphasized the importance of understanding the competitive landscape and the unmet needs in CNS disorders [10][12] Other Important Information - The company is planning an R&D day to discuss clinical programs and a commercial day to highlight launch strategies for ulixacaltamide and relutrigine [16] - Elsunersen is being developed for a rare genetic epilepsy, with a potential NDA submission expected next year [15][16] Q&A Session Summary Question: Can you walk us through the pre-commercial activities and cadence throughout 2026? - The company is making key hires and building inventory for strong launches, focusing on disease awareness for ulixacaltamide [22] Question: What additional new data can we expect at AAN? - The company will present about 15 different presentations, focusing on the Essential3 program and clinical data [25] Question: What is the status of alternative titration schedules for ulixacaltamide? - The company has proposed alternative titration schedules to the FDA and is awaiting their decision [29] Question: How much capital allocation should be expected between relutrigine and ulixacaltamide? - More allocation is expected for ulixacaltamide due to its broader market potential [31] Question: What is the review timeline for the NDAs? - The company has requested priority review for relutrigine but not for ulixacaltamide, considering strategic business reasons [43][44] Question: Can we expect long-term follow-up data at AAN? - The company plans to present long-term efficacy data to reinforce the value of ulixacaltamide [51] Question: What are the expectations for the EMBRAVE study? - The EMBRAVE study is expected to provide valuable data, with a focus on safety and efficacy [81][84]

Financial Data and Key Metrics Changes - In Q4 2025, operating expenses totaled $97 million, up from $71.4 million in Q4 2024, with R&D expenses at $77.5 million and G&A at $19.5 million [17] - For the full year 2025, operating expenses reached $326 million, compared to $209 million in 2024 [17] - The cash position at the end of Q4 2025 was $926 million, significantly increased from $469 million at the end of 2024, primarily due to proceeds from a follow-on public offering [18] Business Line Data and Key Metrics Changes - Ulixacaltamide showed positive results in the Essential3 program, with significant improvements in key endpoints, leading to a breakthrough designation from the FDA [8][9] - Relutrigine demonstrated strong efficacy in the EMBOLD study for SCN2A and SCN8A DEEs, with a potential annual revenue of $5 billion [12] - Vormatrigine achieved a 58% reduction in seizures at week 1 in the RADIANT phase 2 study, with expectations for multiple readouts in the next 12-18 months [13][14] Market Data and Key Metrics Changes - The addressable population for ulixacaltamide in the U.S. is estimated at 2 million patients with essential tremor, with a peak potential revenue of over $10 billion annually [9][10] - The initial addressable population for relutrigine is approximately 10,000 patients in the U.S., with a broader potential of over 200,000 patients with DEE [12] - Vormatrigine targets approximately 3 million people in the U.S. suffering from common epilepsies, with potential annual revenue exceeding $4 billion [14] Company Strategy and Development Direction - The company aims to transform into a commercial entity with two NDA submissions for ulixacaltamide and relutrigine, focusing on enhancing its clinical portfolio [6][16] - Preparations for the commercial launch of ulixacaltamide include building a commercial organization and a comprehensive medical education campaign [10][22] - The company is strategically focused on the U.S. market while acknowledging the unmet need for treatments outside the U.S. [86] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming year, highlighting a strong balance sheet and the potential for significant revenue opportunities across its CNS portfolio [17][19] - The company is positioned for a catalyst-rich year with multiple readouts from its innovative pipeline and plans for an R&D day to discuss clinical programs [16] - Management emphasized the importance of understanding the disease and clinical data for prescribers as part of their pre-commercial activities [24][25] Other Important Information - The company has initiated pre-launch activities for both ulixacaltamide and relutrigine, including key hires and inventory building [22][31] - The EMBRAVE3 trial for elsunersen has been updated to a single-arm, baseline-controlled study, with expectations for completion later this year [15][81] Q&A Session Summary Question: Can you walk us through the pre-commercial activities and cadence throughout 2026? - The company is making key hires and building inventory for strong launches, focusing on disease awareness and prescriber education [22] Question: What additional data can we expect at AAN? - The company will present about 15 different presentations, focusing on the Essential3 program and clinical data [25] Question: What is the status of alternative titration schedules for Relyxa? - The FDA did not require additional studies for alternative titration schedules, and the company is focused on ensuring the drug's tolerability [29][30] Question: How will the POWER3 study help move towards the front line setting? - The study aims to address the needs of a broader patient population with focal seizures, focusing on those who are not well managed with current treatments [40][41] Question: Why did you not request priority review for ulixacaltamide? - The decision was based on strategic considerations regarding launch timing and maximizing long-term revenue potential [43][44] Question: Can we expect long-term follow-up data at AAN? - The company plans to present multiple follow-up data points to reinforce the drug's value [51] Question: What is the expected utility of relutrigine across the DEE spectrum? - The company anticipates that relutrigine will serve as a foundational therapy for a diverse group of DEE patients [68][69]

Financial Data and Key Metrics Changes - In Q4 2025, operating expenses totaled $97 million, up from $71.4 million in Q4 2024, with R&D expenses at $77.5 million and G&A at $19.5 million [16] - For the full year 2025, operating expenses reached $326 million, compared to $209 million in 2024 [16] - The cash position at the end of Q4 2025 was $926 million, significantly increased from $469 million at the end of 2024, primarily due to net proceeds from a follow-on public offering [17] Business Line Data and Key Metrics Changes - Ulixacaltamide showed positive results in the Essential3 program, leading to an NDA submission for essential tremor, with a potential market of over $10 billion annually [7][8] - Relutrigine demonstrated significant efficacy in the EMBOLD study for SCN2A and SCN8A DEEs, with an addressable population of approximately 10,000 patients in the US, and potential annual revenue of $5 billion [9][10] - Vormatrigine achieved a 58% reduction in seizures at week 1 in the RADIANT phase 2 study, with potential annual revenue exceeding $4 billion [12] Market Data and Key Metrics Changes - The addressable population for ulixacaltamide in the US is estimated at 2 million patients with essential tremor [7] - The broader DEE population for relutrigine is over 200,000 patients, with ongoing studies to assess its efficacy [10] - The potential market for elsunersen is projected to exceed $1 billion annually, targeting gain-of-function SCN2A DEEs [15] Company Strategy and Development Direction - The company aims to transition into a commercial entity with two NDA submissions in early 2026 and plans for a robust commercial launch strategy [15] - Focus on building a commercial organization and preparing for product launches, including disease awareness campaigns [21][22] - The company is strategically prioritizing ulixacaltamide for a broader market while planning for relutrigine's expansion based on ongoing studies [43][32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming year, highlighting the potential for significant revenue growth from their innovative pipeline [15] - The company is well-capitalized with approximately $1.5 billion in cash, expected to fund operations into 2028 [18] - Management emphasized the importance of a smooth review process with the FDA and the need for effective communication with prescribers [23][24] Other Important Information - The company plans to present extensive data at the upcoming American Academy of Neurology meeting, focusing on ulixacaltamide and relutrigine [24] - The EMBRAVE3 trial for elsunersen has been updated to a single-arm design, which management believes will enhance the understanding of the drug's impact [82] Q&A Session Summary Question: Can you walk us through the pre-commercial activities currently happening? - The company is making key hires and ensuring sufficient inventory for expected strong launches, particularly for ulixacaltamide [21] Question: What additional data can we expect at AAN? - The company will present about 15 different presentations, focusing on the Essential3 program and clinical data [24] Question: What is the status of alternative titration schedules for relutrigine? - The FDA does not expect additional studies for alternative titration schedules, and the company is focused on ensuring the drug's tolerability [28] Question: How will the POWER3 study help move towards front-line settings? - The study aims to address the needs of a broader patient population with focal seizures, potentially moving vormatrigine to first-line treatment [40] Question: What are the review timelines for the NDAs? - The company has requested priority review for relutrigine but opted for standard review for ulixacaltamide due to strategic considerations [43]

Core Insights - Praxis Precision Medicines has submitted two New Drug Applications (NDAs) for ulixacaltamide and relutrigine, targeting essential tremor and developmental and epileptic encephalopathies respectively, with pre-launch activities expected to accelerate through 2026 [1][3][4] - The company reported a significant increase in cash and investments, totaling $926 million as of December 31, 2025, and net proceeds of $621 million from a public offering in January 2026, which will fund operations into 2028 [10][11] Company Updates - The CEO highlighted a successful fourth quarter with multiple clinical and regulatory advancements, positioning the company for a transition into a commercial entity pending positive reviews of the NDAs [3] - Praxis is scaling its commercial organization and preparing for the launch of ulixacaltamide and relutrigine, including building inventory and initiating disease awareness campaigns [6][10] Financial Performance - As of December 31, 2025, Praxis reported cash, cash equivalents, and marketable securities of $926.1 million, a substantial increase from $469.5 million in 2024, primarily due to proceeds from a public offering [10] - Research and development expenses for Q4 2025 were $77.5 million, up from $56.3 million in Q4 2024, with total R&D expenses for the year reaching $267.1 million compared to $152.4 million in 2024 [11][12] - The company incurred a net loss of $88.9 million for Q4 2025, compared to a loss of $58.7 million in Q4 2024, and a total net loss of $303.3 million for the year [14][29] Product Development - Ulixacaltamide is the first investigational therapy to show positive results in a Phase 3 program for essential tremor, with Breakthrough Therapy Designation granted by the FDA [4][17] - Relutrigine has been granted Breakthrough Therapy Designation and Orphan Drug Designation by the FDA, targeting sodium channel modulation for developmental epileptic encephalopathies [5][19] - Vormatrigine, another product in development, is positioned as a best-in-class therapy for focal onset seizures and generalized epilepsy, with topline results expected in 2026 [8][11] Upcoming Milestones - Praxis plans to present results from the Essential3 program at the American Academy of Neurology Annual Meeting in April 2026, which will further support the launch of ulixacaltamide [4][6] - The EMERALD study for relutrigine is progressing well, with full enrollment expected in the second half of 2026, potentially leading to a supplemental NDA submission in 2027 [6][10]

Group 1 - Praxis Precision Medicines Inc. (NASDAQ:PRAX) is recognized as one of the 13 stocks with significant upside potential, with Wells Fargo initiating coverage with an Equal Weight rating and a price target of $282, while noting a 50% probability of success for its investigational drug ulixacaltamide [1][3] - The company anticipates potential peak revenue of up to $20 billion over the next 24 months from four drugs, including $10 billion from ulixacaltamide, $5 billion from relutrigine, $4 billion from vormatrigine for epilepsy, and around $1 billion from elsunersen [2] - Praxis is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance [3]

Core Insights - Praxis Precision Medicines (NASDAQ:PRAX) is identified as one of the 17 biotechnology stocks with significant upside potential, with analysts projecting over 140% upside [1] - Guggenheim analyst Yatin Suneja raised the price target for PRAX from $760 to $800, maintaining a Buy rating based on the market adoption potential of ulixacaltamide in essential tremor, which supports a market opportunity exceeding $15 billion [2] - H.C. Wainwright analyst Douglas Tsao also raised the price target for PRAX from $340 to $1,245, indicating a revised upside potential of 274% [3] Product and Market Potential - Ulixacaltamide is considered transformative for Praxis, with peak sales projections ranging from $5 billion to $10 billion, while relutrigine is expected to drive significant value with peak sales reaching $6.8 billion [4] - The company focuses on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, including epilepsy, movement disorders, and depression [5]